Posted by Michael Wonder on 01 Mar 2017
Recommendations on eligibility to PRIME scheme - February 2017
1 March 2017 - During its February 2017 meeting, the CHMP reviewed 5 recommendations for eligibility to PRIME: 2 were granted and 3 were denied.
Eligibility was granted for:
- PF-06838435/SPK- 9001 for the treatment of haemophilia B
- Givosiran for the prevention of acute attacks of hepatic porphyria
